Eric S. Langer and Ronald A. Rader, BioPlan Associates || April 1, 2015 Now that the FDA has just approved its first product under biosimilar regulations—Zarxio—containing filgrastim (G-CSF), a biosimilar version of Neupogen from Amgen, we can expect some more rapid shifts in the market. Factors like how this…
Jim Miller, President, PharmSource || October 1, 2014 Where is the CMO industry headed?
– Propensity to outsource
– Formulary acceptance for new drugs
– Industry consolidation
– Future depends on new approvals for small and mid-size